drugset / Trial / NCT03268226

Functional Respiratory Imaging Study (FRI)

NCT03268226

Phase 3 Completed 20 enrolled Chiesi Farmaceutici S.p.A.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients

Timeline

Start
2017-11-20
Primary completion
2019-01-30
Completion
2019-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 6 ug Inhaled
Subject Glycopyrronium Unknown 12.5 ug Inhaled
Subject beclomethasone dipropionate Other / unclassified 100 ug Inhaled